Photodynamic and Pharmacologic Treatment of Choroidal Neovascularization (Photodynamic Booster Study)
Photodynamic and Pharmacologic Treatment of Choroidal Neovascularization (Photodynamic Booster Study)
The goal of this pilot study is to validate the use of the combination of Lucentis (ranibizumab) and Visudyne (verteporfin) in the treatment of choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) and to explore the use of a volumetric analysis of the CNV lesion to determine disease activity, response to therapy, and as a tool for determining the need for retreatment.
Inclusion Criteria: